HIV

Showing 15 posts of 200 posts found.

landing-hero-images1

ViiV’s two-drug regimen gets EU approval for HIV-1

May 22, 2018
Manufacturing and Production, Sales and Marketing EMA, EU, Europe, HIV, Juluca, ViiV Healthcare, pharma

ViiV Healthcare has announced that its HIV therapy Juluca (dolutegravir/rilpivirine) has been awarded marketing authorisation in the EU from the …

aaron_traywick

Startup CEO who injected untested herpes cure during live stream found dead

May 2, 2018
Research and Development Aaron Traywick, Ascendance Biomedical, HIV, herpes, pharma

Aaron Traywick, the 28-year-old CEO of biotech startup Ascendance Biomedical who made headlines when he injected himself with an untested …

FDA greenlights alternative therapy for multidrug-resistant HIV patients

March 7, 2018
Research and Development, Sales and Marketing HIV, Theratechnologies, Trogarzo, pharma

Theratechnologies has revealed that Trogarzo has received approval from the FDA as a treatment of HIV-1 in patients with multidrug-resistant …

gilead_hq_at_stockley_park_london

Switching to Gilead’s Biktarvy proves non-inferior in HIV patients

March 6, 2018
Manufacturing and Production, Research and Development Biktarvy, Gilead, HIV, pharma

Gilead has unveiled findings from two Phase 3 studies into the efficacy of switching to its three-drug combo Biktarvy (bictegravir/emtricitabine/tenofovir …

gilead-sciences

Gilead investigational data gives hope for HIV eradication in humans

March 5, 2018
Research and Development, Sales and Marketing Gilead, HIV, pharma

Gilead has lifted the curtain on new preclinical data on the efficacy of a combo therapy of GS-9620, its investigational …

gilead-sciences

FDA approves Gilead’s Biktarvy for HIV as Viiv Healthcare launches patent lawsuit

February 8, 2018
Sales and Marketing Biktarvy, FDA, GSK, Gilead, HIV, Pfizer, Shionogi, US, ViiV Healthcare, descovy, pharma

Gilead has announced that its daily single-tablet therapy Biktarvy has received FDA approval for HIV-1 infection.

truvada-web

AIDS charity lambasts “ethically challenged” Gilead over price hikes

January 11, 2018
Sales and Marketing AIDS, Gilead, HIV, Truvada, biotech, drugs, pharma, pharmaceutical

The AIDS Healthcare Foundation (AHF) has strongly criticised Gilead prices increases across the board for its HIV and AIDS treatment, …

mit-drug-delivery-01_0

Slow-release, once-weekly pill for HIV developed

January 10, 2018
Research and Development HIV, Lyndra, biotech, drugs, pharma, pharmaceutical

Patient adherence is a big issue across the healthcare system, where individuals, even with the most serious conditions, do not …

hiv_aids

The global HIV/AIDS movement

November 27, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AIDS, HIV, International HIV/AIDS Alliance

Increasingly collaborative efforts have seen the threat of HIV recede and brought hope to demographics and communities most vulnerable to …

640px-hiv-budding-color

Learning lessons from HIV to change the treatment access landscape

November 23, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, HIV, pharma

Greg Alton, Executive Vice President of Corporate and Medical Affairs at Gilead, reveals how the rapid development and distribution of …

gsk_boronia_australia

FDA approves first-ever two-drug HIV regimen, GSK’s Juluca

November 22, 2017
Research and Development, Sales and Marketing AIDS, FDA, GSK, Gilead, GlaxoSmithKilne, HIV, Juluca, ViiV Healthcare, pharma

GlaxoSmithKline has announced that the FDA has awarded US marketing authorisation to the first two-drug regimen in the treatment of …

shutterstock_273326141

Partnerships hold the key to making HIV history

November 20, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, Janssen, pharma

Brian Woodfall, Global Head of Late Development, Infectious Diseases at Janssen, explains why a future without HIV can only be …

4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

September 29, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, EMA, FDA, HIV, J&J, JJ, Kevzara, Mylan, NICE, Sanofi, nash, top ten

It’s Friday, and it’s time for another round up of the most popular articles on pharmafile.com over the last seven …

The Gateway to Local Adoption Series

Latest content